Acinetobacter baumannii Infection
Learn about Acinetobacter baumannii infection diagnosis, including clinical documentation and medical coding for healthcare professionals. Find information on MDR Acinetobacter infection and Acinetobacter sepsis, covering symptoms, treatment, and prevention. This resource supports accurate medical coding and improved patient care for Acinetobacter baumannii infections.
Bacterial infection often resistant to multiple antibiotics, caused by Acinetobacter baumannii.
Pneumonia, bloodstream infections, wound infections, urinary tract infections. Symptoms vary depending on infection site.
Hospitals, especially intensive care units (ICUs), and healthcare facilities.
ICD-10 Code Families
Complete code families applicable to B96.89
When to use each related code
| Description | When to use |
|---|---|
| Infection caused by Acinetobacter baumannii bacteria. | Use for infections confirmed as caused by A. baumannii. Consider drug resistance status. |
| Multi-drug resistant Acinetobacter baumannii infection. | Use when A. baumannii infection shows resistance to multiple antibiotic classes. |
| Bloodstream infection caused by Acinetobacter baumannii. | Use when A. baumannii is isolated from blood cultures, indicating sepsis. |
Best-practice checklist
- ✓Acinetobacter baumannii infection confirmed via culture
- ✓Document antibiotic resistance profile (if applicable)
- ✓Specify infection site (e.g., pneumonia, UTI)
- ✓Record patient's risk factors (e.g., ICU stay, invasive devices)
- ✓Document sepsis criteria if present (e.g., qSOFA, SOFA)
Common pitfalls to avoid
Coding sepsis solely based on "Acinetobacter" presence without documented organ dysfunction can lead to inaccurate DRG assignment and overcoding.
Documenting and coding multi-drug resistance (MDR) requires specific antibiotic susceptibility results. Lack of clarity may cause undercoding and lost revenue.
Missing documentation of the infection site (e.g., pneumonia, UTI) for Acinetobacter can hinder accurate code assignment and impact quality metrics.
Best-practice tips
- 01Isolate patients with MDR Acinetobacter. Implement contact precautions.
- 02Promote meticulous hand hygiene. Use alcohol-based sanitizer or soap and water.
- 03Ensure proper disinfection of equipment. Follow infection control guidelines.
- 04Optimize antibiotic stewardship. Implement rapid diagnostics and targeted therapies.
- 05Conduct active surveillance cultures. Monitor for outbreaks and implement control measures.
Step-by-step checklist
- 1
Verify patient has positive culture for Acinetobacter baumannii.
- 2
Review recent antibiotic use and hospitalization history.
- 3
Assess for signs/symptoms of infection (fever, hypotension, etc.).
- 4
Check for local resistance patterns to guide antibiotic choice.
Ready-to-paste narrative
Patient presents with signs and symptoms suggestive of Acinetobacter baumannii infection, including [specify presenting symptoms, e.g., fever, chills, hypotension, tachypnea, purulent sputum, altered mental status]. Differential diagnosis includes pneumonia, sepsis, urinary tract infection, wound infection, and other nosocomial infections. The patient's medical history includes [list relevant medical history, e.g., recent hospitalization, intubation, indwelling catheters, antibiotic use, immunocompromised status]. Physical examination reveals [document relevant findings, e.g., fever of [temperature], tachycardia, respiratory distress, localized signs of infection]. Laboratory studies were ordered, including complete blood count with differential, blood cultures, urinalysis, and culture of the suspected infection site. Preliminary findings indicate [mention preliminary lab results, e.g., leukocytosis, elevated procalcitonin, positive gram-negative bacilli on Gram stain]. Based on the clinical presentation and preliminary laboratory data, the presumptive diagnosis is Acinetobacter baumannii infection. Given the potential for multi-drug resistance (MDR Acinetobacter), empiric antibiotic therapy was initiated with [specify antibiotic regimen, e.g., carbapenem, colistin, aminoglycoside] pending culture and sensitivity results. The patient will be closely monitored for response to treatment and development of complications, such as septic shock or organ dysfunction. Infection control precautions have been implemented to prevent further spread. Further diagnostic testing, including imaging studies, may be warranted depending on the patient's clinical course. ICD-10 code [appropriate code, e.g., A49.1, J15.0, B96.2 depending on the site of infection] is considered. Treatment plan includes continued monitoring, supportive care, and adjustment of antibiotic therapy based on culture and sensitivity results. The patient's prognosis will be reassessed based on response to therapy and potential complications.
Common questions and answers
What are the most effective empiric antibiotic treatment options for suspected multi-drug resistant Acinetobacter baumannii infection in critically ill patients?+
Empiric antibiotic treatment for suspected MDR Acinetobacter baumannii infection in critically ill patients is complex due to widespread resistance. Current guidelines recommend combination therapy based on local antibiograms and resistance patterns. Commonly used options include a carbapenem (if not significantly resistant), sulbactam (often combined with ampicillin), or colistin (polymyxin E) often in combination with another agent like minocycline or tigecycline. For extremely drug-resistant strains, newer agents like cefiderocol or eravacycline may be considered where available. Rapid diagnostics, including PCR and susceptibility testing, are crucial for tailoring therapy and optimizing patient outcomes. Explore how antimicrobial stewardship programs can optimize antibiotic selection and minimize the development of further resistance. Learn more about the latest resistance trends in your region by consulting local surveillance data.
How can clinicians differentiate Acinetobacter baumannii sepsis from other causes of sepsis in ventilated patients based on clinical presentation and diagnostic tests?+
Differentiating Acinetobacter baumannii sepsis from other causes of sepsis in ventilated patients can be challenging due to overlapping symptoms. Clinical clues may include risk factors such as prolonged hospitalization, prior antibiotic exposure, invasive procedures, and presence of indwelling devices. Acinetobacter infections are frequently associated with ventilator-associated pneumonia (VAP). While clinical presentation alone is insufficient, purulent sputum, worsening oxygenation, and new or persistent fever may raise suspicion. Definitive diagnosis requires laboratory confirmation. Blood cultures, though not always positive in Acinetobacter sepsis, should be obtained. Respiratory samples, such as bronchoalveolar lavage (BAL) or endotracheal aspirates, should be sent for Gram stain and culture. Consider implementing rapid diagnostic tests like PCR for quicker identification. Learn more about the role of biomarkers like procalcitonin in diagnosing and managing sepsis.
What infection control measures are most effective in preventing the spread of Acinetobacter baumannii in intensive care units and healthcare settings?+
Preventing the spread of Acinetobacter baumannii in healthcare settings, particularly ICUs, requires a multi-pronged approach. Strict adherence to hand hygiene protocols is paramount. Contact precautions, including gloves and gowns, should be implemented for all patients colonized or infected with Acinetobacter. Environmental cleaning and disinfection of frequently touched surfaces, medical equipment, and patient rooms are crucial. Consider implementing active surveillance cultures to identify colonized patients early and initiate appropriate isolation measures. Optimizing antibiotic use through antimicrobial stewardship programs can help minimize the emergence and spread of resistant strains. Explore how cohorting patients colonized or infected with Acinetobacter can further limit transmission. Learn more about the importance of educating healthcare staff on effective infection control practices to combat Acinetobacter baumannii and other multi-drug resistant organisms.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.